Abstract
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the central nervous system caused by the JC papovavirus, and is a well known complication in patients with lymphoproliferative diseases (LPDs) during chemotherapy. We report the case of a 59-year-old woman affected by B-cell LPD who underwent three cycles of chemotherapy with fludarabine and rituximab and developed atypical PML six months after the last cycle of chemotherapy. Our patient showed the following peculiarities: chemotherapy regimen was neither heavy nor prolonged; the onset of neurological symptoms was unexpectedly late; the MRI lesion was atypical for non-HIV-related PML, being monofocal and infratentorial with early gadolinium (Gd) enhancement and mass effect; survival was rather prolonged despite the lack of treatment. These data suggest that in patients with LPDs, the occurrence of progressive neurological deficits should induce the suspicion of PML even when clinical onset is late (with respect to chemotherapy) and in the presence of a single infratentorial lesion, with Gd enhancement and mass effect.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Astrom KE, Mancall EL, Richardson Jr EP (1958) Progressive multifocal leukoencephalopathy: a hitherto unrecognised complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain 81:93–111
Van Assche G, Van Ranst M, Sciot R et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 353:362–368
Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369–374
Langer-Gould A, Atlas SW, Green AJ et al (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375–381
Garcia-Suarez J, de Miguel D, Krsnik I et al (2005) Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 80:271–281
Kastrup O, Wanke I, Esser S, Maschke M (2005) Evolution of purely infratentorial PML under HAART-negative outcome under rapid immune reconstitution. Clin Neurol Neurosurg 107:509–513
Weber F, Goldmann C, Kramer M et al (2001) Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol 49:636–642
Li YY, Perez HD, Zollner TM (2006) Fatalities in natalizumab treatment — a ‘no go’ for leukocyte recirculation approaches? Expert Opin Ther Targets 10:489–499
Anaissie EJ, Kontoyiannis DP, O’Brien S et al (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129:559–566
Matteucci P, Magni M, Di Nicola M et al (2002) Leukoencephalopathy and papova virus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 100:1104–1105
Hammarin AL, Bogdanovic G, Svedem V et al (1996) Analysis of PCR as a tool for detection of JC Virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy. J Clin Microbiol 34:2929–2932
Elphick GF, Querbes W, Jordan JA et al (2004) The human poly-omavirus, JCV, uses serotonin receptors to infect cells. Science 306:1380–1383
Altschuler EL, Kast RE (2005) The atypical antipsychotic agents zisprasidone, risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses 65:585–586
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bonavita, S., Conforti, R., Russo, A. et al. Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab. Neurol Sci 29, 37–39 (2008). https://doi.org/10.1007/s10072-008-0857-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-008-0857-x